Silverback Therapeutics is a biopharmaceutical company focused on utilizing its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. Co. has engineered SBT8230 to treat chronic hepatitis B virus by eliciting an anti-viral immune response through targeting TLR8 activation to the liver. SBT8230 is comprised of an ASGR1 monoclonal antibody conjugated to the same TLR8 linker-payload as SBT6050, but with an average drug antibody ratio (DAR) of about two as opposed to the average DAR of about four used in SBT6050. We show 8 historical shares outstanding datapoints in our SBTX shares outstanding history coverage, used to compute SBTX market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing SBTX market cap history over the course of time is important for investors
interested in comparing SBTX's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of SBTX versus a peer is one thing; comparing
SBTX market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like SBTX can fluctuate over the course of history.
With this page we aim to empower investors researching SBTX by allowing them to research the SBTX market cap history. |
Free SBTX Email Alerts:
Video: The Importance of Market Cap
